Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle

Yanan Shi,1,2,* Wan Huang,1,* Rongcai Liang,1–3 Kaoxiang Sun,2,3 Fangxi Zhang,2,3 Wanhui Liu,2,3 Youxin Li1–31College of Life Science, Jilin University, Changchun, China; 2State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Co, Ltd,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shi YN, Huang W, Liang RC, Sun KX, Zhang FX, Liu WH, Li YX
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/002c171b43954946822879cc63ad2285
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:002c171b43954946822879cc63ad2285
record_format dspace
spelling oai:doaj.org-article:002c171b43954946822879cc63ad22852021-12-02T02:31:36ZImprovement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle1176-91141178-2013https://doaj.org/article/002c171b43954946822879cc63ad22852012-12-01T00:00:00Zhttp://www.dovepress.com/improvement-of-in-vivo-efficacy-of-recombinant-human-erythropoietin-by-a11817https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Yanan Shi,1,2,* Wan Huang,1,* Rongcai Liang,1–3 Kaoxiang Sun,2,3 Fangxi Zhang,2,3 Wanhui Liu,2,3 Youxin Li1–31College of Life Science, Jilin University, Changchun, China; 2State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Co, Ltd, Yantai, China; 3School of Pharmacy, Yantai University, Yantai, China*These authors contributed equally to this workAbstract: To improve the pharmacokinetics and stability of recombinant human erythropoietin (rhEPO), rhEPO was successfully formulated into poly(ethylene glycol)–poly(d,l-lactide) (PEG–PLA) di-block copolymeric micelles at diameters ranging from 60 to 200 nm with narrow polydispersity indices (PDIs; PDI < 0.3) and trace amount of protein aggregation. The zeta potential of the spherical micelles was in the range of −3.78 to 4.65 mV and the highest encapsulation efficiency of rhEPO in the PEG–PLA micelles was about 80%. In vitro release profiles indicated that the stability of rhEPO in the micelles was improved significantly and only a trace amount of aggregate was found. Pharmacokinetic studies in rats showed highly enhanced plasma retention time of the rhEPO-loaded PEG-PLA micelles in comparison with the native rhEPO group. Increased hemoglobin concentrations were also found in the rat study. Native polyacrylamide gel electrophoresis results demonstrated that rhEPO was successfully encapsulated into the micelles, which was stable in phosphate buffered saline with different pHs and concentrations of NaCl. Therefore, PEG–PLA micelles can be a potential protein drug delivery system.Keywords: rhEPO, PEG–PLA micelle, in vitro, pharmacokinetics, pharmacodynamicsShi YNHuang WLiang RCSun KXZhang FXLiu WHLi YXDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 1-11 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Shi YN
Huang W
Liang RC
Sun KX
Zhang FX
Liu WH
Li YX
Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
description Yanan Shi,1,2,* Wan Huang,1,* Rongcai Liang,1–3 Kaoxiang Sun,2,3 Fangxi Zhang,2,3 Wanhui Liu,2,3 Youxin Li1–31College of Life Science, Jilin University, Changchun, China; 2State Key Laboratory of Long-acting and Targeting Drug Delivery System, Luye Pharmaceutical Co, Ltd, Yantai, China; 3School of Pharmacy, Yantai University, Yantai, China*These authors contributed equally to this workAbstract: To improve the pharmacokinetics and stability of recombinant human erythropoietin (rhEPO), rhEPO was successfully formulated into poly(ethylene glycol)–poly(d,l-lactide) (PEG–PLA) di-block copolymeric micelles at diameters ranging from 60 to 200 nm with narrow polydispersity indices (PDIs; PDI < 0.3) and trace amount of protein aggregation. The zeta potential of the spherical micelles was in the range of −3.78 to 4.65 mV and the highest encapsulation efficiency of rhEPO in the PEG–PLA micelles was about 80%. In vitro release profiles indicated that the stability of rhEPO in the micelles was improved significantly and only a trace amount of aggregate was found. Pharmacokinetic studies in rats showed highly enhanced plasma retention time of the rhEPO-loaded PEG-PLA micelles in comparison with the native rhEPO group. Increased hemoglobin concentrations were also found in the rat study. Native polyacrylamide gel electrophoresis results demonstrated that rhEPO was successfully encapsulated into the micelles, which was stable in phosphate buffered saline with different pHs and concentrations of NaCl. Therefore, PEG–PLA micelles can be a potential protein drug delivery system.Keywords: rhEPO, PEG–PLA micelle, in vitro, pharmacokinetics, pharmacodynamics
format article
author Shi YN
Huang W
Liang RC
Sun KX
Zhang FX
Liu WH
Li YX
author_facet Shi YN
Huang W
Liang RC
Sun KX
Zhang FX
Liu WH
Li YX
author_sort Shi YN
title Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
title_short Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
title_full Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
title_fullStr Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
title_full_unstemmed Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG–PLA micelle
title_sort improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in peg–pla micelle
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/002c171b43954946822879cc63ad2285
work_keys_str_mv AT shiyn improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
AT huangw improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
AT liangrc improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
AT sunkx improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
AT zhangfx improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
AT liuwh improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
AT liyx improvementofinvivoefficacyofrecombinanthumanerythropoietinbyencapsulationinpegampndashplamicelle
_version_ 1718402386023677952